J&J

Showing 15 posts of 219 posts found.

nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

usmarinetankinbaghdad

Lawsuit alleges pharma giants funded terror in Iraq

August 2, 2018
Business Services, Medical Communications, Sales and Marketing AstraZeneca, Iraq War, J&J, JJ, Litigation, Roche, corruption, terrorism

The United States Justice Department is investigating claims that major pharmaceutical and medical device companies were aware that supplies that …

top_10_image

Top Ten most popular articles on Pharmafile.com this week

July 20, 2018
Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10

As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …

jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

johnson_and_johnson_jj

J&J ordered to pay $4.68 billion to talc-powder plaintiffs

July 13, 2018
Medical Communications J&J, JJ, Johnson and Johnson, legal, talc powder

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women …

Missouri appeals court overturns $55m J&J verdict

July 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Litigation, appeal, pharma

A $55 million verdict against the multinational pharmaceutical company Johnson & Johnson has been overturned by an appeals court in …

sandi_peterson

J&J’s second-in-command to retire, alongside executive restructure

June 25, 2018
Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …

janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

Latest content